See more : Taiko Pharmaceutical Co.,Ltd. (4574.T) Income Statement Analysis – Financial Results
Complete financial analysis of NanoString Technologies, Inc. (NSTG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NanoString Technologies, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- AmidA Holdings Co.,Ltd. (7671.T) Income Statement Analysis – Financial Results
- Saudi Pharmaceutical Industries and Medical Appliances Corporation (2070.SR) Income Statement Analysis – Financial Results
- Apollo Pipes Limited (APOLLOPIPE.NS) Income Statement Analysis – Financial Results
- Kajaria Ceramics Limited (KAJARIACER.BO) Income Statement Analysis – Financial Results
- Toyo Tire Corporation (5105.T) Income Statement Analysis – Financial Results
NanoString Technologies, Inc. (NSTG)
About NanoString Technologies, Inc.
NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 127.26M | 145.09M | 117.32M | 125.57M | 106.73M | 114.91M | 86.49M | 62.67M | 47.59M | 31.40M | 22.97M | 17.80M | 11.73M | 34.42M |
| Cost of Revenue | 65.48M | 68.30M | 52.41M | 44.04M | 36.33M | 31.88M | 30.25M | 26.13M | 21.15M | 15.01M | 12.36M | 9.78M | 9.13M | 21.12M |
| Gross Profit | 61.79M | 76.78M | 64.91M | 81.53M | 70.40M | 83.03M | 56.24M | 36.54M | 26.44M | 16.39M | 10.61M | 8.02M | 2.60M | 13.30M |
| Gross Profit Ratio | 48.55% | 52.92% | 55.33% | 64.93% | 65.96% | 72.26% | 65.03% | 58.31% | 55.56% | 52.21% | 46.19% | 45.07% | 22.18% | 38.64% |
| Research & Development | 70.84M | 69.50M | 62.86M | 68.04M | 61.60M | 46.89M | 34.72M | 24.60M | 21.40M | 14.98M | 11.64M | 8.99M | 7.55M | 19.09M |
| General & Administrative | 133.83M | 110.70M | 86.70M | 90.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 9.30M | 4.80M | 3.40M | 5.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 143.13M | 115.50M | 90.10M | 96.20M | 78.20M | 74.33M | 62.70M | 53.19M | 51.06M | 29.91M | 15.49M | 9.53M | 8.03M | 36.90M |
| Other Expenses | -1.92M | -20.00K | -971.00K | -929.00K | -1.66M | 183.00K | -515.00K | -389.00K | -147.00K | -66.00K | -29.00K | 80.00K | 254.00K | 0.00 |
| Operating Expenses | 213.97M | 185.01M | 152.95M | 164.23M | 139.79M | 121.22M | 97.42M | 77.78M | 72.47M | 44.89M | 27.12M | 18.52M | 15.57M | 55.98M |
| Cost & Expenses | 279.45M | 253.31M | 205.36M | 208.27M | 176.13M | 153.10M | 127.67M | 103.91M | 93.62M | 59.90M | 39.48M | 28.30M | 24.70M | 77.10M |
| Interest Income | 2.41M | 649.00K | 1.74M | 2.82M | 1.33M | 809.00K | 390.00K | 233.00K | 272.00K | 68.00K | 21.00K | 10.00K | 29.00K | 0.00 |
| Interest Expense | 7.54M | 7.49M | 15.41M | 8.49M | 7.43M | 6.15M | 5.67M | 4.02M | 4.14M | 1.94M | 804.00K | 599.00K | 94.00K | -1.89M |
| Depreciation & Amortization | 492.00K | 629.00K | 773.00K | 1.89M | 4.07M | 3.35M | 2.98M | 2.38M | 1.54M | 1.78M | 1.95M | 1.45M | 972.00K | 0.00 |
| EBITDA | -143.58M | -101.73M | -88.05M | -82.70M | -65.65M | -34.84M | -38.32M | -39.02M | -44.31M | -26.51M | -14.96M | -8.88M | -11.70M | -42.68M |
| EBITDA Ratio | -119.20% | -74.16% | -74.39% | -64.36% | -65.32% | -32.38% | -47.75% | -66.06% | -96.44% | -90.74% | -63.42% | -50.29% | -99.89% | -123.99% |
| Operating Income | -152.18M | -108.23M | -88.05M | -82.70M | -69.39M | -38.20M | -41.18M | -41.24M | -46.02M | -28.50M | -16.51M | -10.50M | -12.97M | -42.68M |
| Operating Income Ratio | -119.58% | -74.59% | -75.05% | -65.86% | -65.02% | -33.24% | -47.61% | -65.81% | -96.70% | -90.75% | -71.86% | -58.97% | -110.59% | -123.99% |
| Total Other Income/Expenses | -7.04M | -6.86M | -21.78M | 42.27M | -7.76M | -5.16M | -5.80M | -4.17M | -4.02M | -784.00K | -1.20M | -436.00K | 204.00K | -1.44M |
| Income Before Tax | -159.23M | -115.09M | -109.83M | -40.43M | -77.15M | -43.36M | -46.97M | -45.42M | -50.04M | -29.28M | -17.71M | -10.93M | -12.77M | -44.12M |
| Income Before Tax Ratio | -125.12% | -79.32% | -93.61% | -32.20% | -72.28% | -37.73% | -54.31% | -72.47% | -105.14% | -93.24% | -77.08% | -61.42% | -108.85% | -128.17% |
| Income Tax Expense | 317.00K | 167.00K | 253.00K | 269.00K | 249.00K | 204.00K | 116.00K | 166.00K | 2.45M | 99.00K | 775.00K | 679.00K | 348.00K | 5.00K |
| Net Income | -159.54M | -115.25M | -110.08M | -40.70M | -77.40M | -43.56M | -47.09M | -45.58M | -50.04M | -29.28M | -17.71M | -10.93M | -12.77M | -44.11M |
| Net Income Ratio | -125.37% | -79.44% | -93.83% | -32.41% | -72.52% | -37.91% | -54.45% | -72.74% | -105.14% | -93.24% | -77.08% | -61.42% | -108.85% | -128.16% |
| EPS | -3.44 | -2.54 | -2.82 | -1.18 | -2.78 | -1.84 | -2.34 | -2.40 | -2.80 | -3.83 | -1.93 | -1.19 | -1.59 | -0.95 |
| EPS Diluted | -3.44 | -2.54 | -2.82 | -1.18 | -2.78 | -1.84 | -2.34 | -2.40 | -2.80 | -3.83 | -1.93 | -1.19 | -1.59 | -0.95 |
| Weighted Avg Shares Out | 46.41M | 45.30M | 39.08M | 34.59M | 27.88M | 23.73M | 20.12M | 19.03M | 17.84M | 7.64M | 9.17M | 9.17M | 8.02M | 46.66M |
| Weighted Avg Shares Out (Dil) | 46.41M | 45.30M | 39.08M | 34.59M | 27.88M | 23.73M | 20.12M | 19.03M | 17.84M | 7.64M | 9.17M | 9.17M | 8.02M | 46.66M |
NanoString Customers Present First Data Using the Most Comprehensive Spatial Proteomics Panel Available
NanoString Technologies (NSTG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Short squeeze alert for October 18th: 2 stocks that could soar
10x Genomics Comments on Second UPC Preliminary Injunction Decision
NanoString Provides Preliminary Financial and Operational Highlights for Third Quarter of 2023
A*STAR's Genome Institute of Singapore, NanoString and Next Level Genomics Establish Joint Lab to Advance Studies of Complex Diseases with Spatial Genomics
10x Wins Injunction From Unified Patent Court Banning Sales of NanoString's CosMx Products in Europe
NanoString Comments on Unified Patent Court Order
NanoString to Host Virtual Spatial Genomics Summit September 19
NanoString Launches the Most Comprehensive Spatial Proteomics Panel Ever Offered
Source: https://incomestatements.info
Category: Stock Reports